-
Testing for endotoxins/pyrogens
according to the European Pharmacopoeia and the United States Pharmacopeia
(USP)
-
Testing for sufficient conservation according to
the European Pharmacopoeia (Pharmacopeia Europaea, Pharm.
Eur.) 5.1.3, NT 2001, S. 421 - 423
-
Testing for sterility according to
the European Pharmacopoeia (Pharmacopoea Europaea, Ph.Eur.), DIN EN ISO
11737-1 (Pharm. Eur. 2.6.1)
-
testing for
sterility (direct feeding or filtration method)
-
validation of
sterilization processes
-
Testing for acute systemic toxicity according to EN 10993-11, Pharm. Eur. III 2.6.8, Pharm. Eur. 1999, Suppl. 2001, 2.6.14
-
anomalous toxicity
-
acute systemic toxicity
-
subacute systemic toxicity
-
subchronic systemic toxicity
-
pyrogenic substances of endotoxic or
non-endotoxic origin (pyrogen test)
-
Biological evaluation of dental
materials according to EN ISO 7405
-
Testing for irritation and
delayed-type hypersensitivity (sensitization, sensitation, sensibilisation) according to EN ISO 10993-10
-
testing for irritation
-
epicutaneous
reaction
-
intracutaneous
(intradermal) reaction
-
testing for
delayed-type hypersensitivity
-
occlusion lobuli
procedure
-
maximization
procedure
-
Identification and quantification of potential
degradation products according to EN ISO 10993-9
-
Testing for local effects after
implantation according to EN ISO 10993-6
-
subcutaneous
implantation test
-
intramuscular
implantation test
-
Testing for cytotoxicity, cytotoxicity testing
according to EN ISO 10993-5, USP XXII (87), AS 2696 App. C. BS 5736 Part 10
-
testing with extracts
-
Testing for hemocompatibility according to
EN ISO 10993-4
-
hemolysis
-
platelet count (thrombocyte count)
-
partial
thromboplastin time
-
complement activation
-
Testing for genotoxicity according to
EN ISO 10993-3
-
Ames test (back mutation test)
-
Testing for
teratogenicity